Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence

5 Jun 2021

Abstract excerpt

The molecular diversity of prostate cancer (PCa) has been demonstrated by recent genome-wide studies, proposing a significant number of different molecular markers. However, only a few of them have been transferred into clinical practice so far. The present study aimed to identify and validate novel DNA methylation biomarkers for PCa diagnosis and prognosis. Microarray-based methylome data of well-characterized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34198725
DOI: 10.3390/ijms22116091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease RecurrencePMID 34198725Read ↗

DNA methylation alterations in prostate cancer: from diagnosis to treatmentSemantic proximity Read ↗

Prognostic DNA Methylation Markers for Prostate CancerSemantic proximity Read ↗

Prediction of Prognosis in Patients with Prostate Cancer by DNA Methylation ClassificationSemantic proximity Read ↗

ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancerSemantic proximity Read ↗

Genomic DNA Methylation-Derived Algorithm Enables Accurate Detection of Malignant Prostate TissuesSemantic proximity Read ↗

An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk.Semantic proximity Read ↗

A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancerSemantic proximity Read ↗

Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsiesSemantic proximity Read ↗

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate CancerSemantic proximity Read ↗

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalitySemantic proximity Read ↗

Epigenetic Markers for Molecular Detection of Prostate CancerSemantic proximity Read ↗

Bioinformatic determination of the expression and clinical value of the histone lysine demethylase family in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.